Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A

European Journal of Heart Failure

Volumn 13, Issue 3, 2011, Pages 278-283

  MacHann, Wolfram ^a   Breunig, Frank ^a   Weidemann, Frank ^a   Sandstede, Jörn ^a   Hahn, Dietbert ^a   Köstler, Herbert ^a   Neubauer, Stefan ^b   Wanner, Christoph ^a   Beer, Meinrad ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiac high energy phosphates; Cardiomyopathy; Enzyme replacement therapy; Hypertrophy; Magnetic resonance spectroscopy

Indexed keywords

ADENOSINE TRIPHOSPHATE; AGALSIDASE BETA; CREATINE PHOSPHATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PRIORITY JOURNAL;

EID: 79951849142     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq211     Document Type: Article

References (35)

1. Desnick RJ, Banikazemi M. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. Nephrol Ther 2006;2(Suppl. 2):S172-S185. (Pubitemid 43156033)
2. Breunig F, Weidemann F, Beer M, Eggert A, Krane V, Spindler M, Sandstede J, Strotmann J, Wanner C. Fabry disease: diagnosis and treatment. Kidney Int Suppl 2003;63:S181-S185. (Pubitemid 36513405)
3. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyo-pathy. Am J Cardiol 2006;97:1515-1518.
4. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myo-cardial interstitium. Eur Heart J 2003;24:2151-2155. (Pubitemid 37486535)
5. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006;8:479-482.
6. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, Steinmann B, Burnier M, Palecek T, Bultas J, Hayoz D. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 2006;26: 839-844. (Pubitemid 43732160)
7. Ingwall JS, Atkinson DE, Clarke K, Fetters JK. Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium. Eur Heart J 1990;11(Suppl. B):108-115. (Pubitemid 20181258)
8. Siakotos AN, Blair PS, Savill JD, Katz ML. Altered mitochondrial function in canine ceroid-lipofuscinosis. Neurochem Res 1998;23:983-989. (Pubitemid 28334246)
9. Lucke T, Hoppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab 2004;82:93-97. (Pubitemid 38523330)
10. Beer M, Seyfarth T, Sandstede J, Landschutz W, Lipke C, Kostler H, von Kienlin M, Harre K, Hahn D, Neubauer S. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002;40:1267-1274.
11. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med 2007;356: 1140-1151. (Pubitemid 46425598)
12. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96:2190-2196. (Pubitemid 27425822)
13. Beer M, Wagner D, Myers J, Sandstede J, Kostler H, Hahn D, Neubauer S, Dubach P. Effects of exercise training on myocardial energy metabolism and ventricular function assessed by quantitative phosphorus-31 magnetic resonance spectroscopy and magnetic resonance imaging in dilated cardiomyopathy. J Am Coll Cardiol 2008;51:1883-1891. (Pubitemid 351615253)
14. Palecek T, Bultas J, Hajek M, Karetova D, Kuchynka P, Kautzner J, Elleder M, Linhart A. Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease. Int J Cardiol 2010;144:337-339.
15. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-529.
16. Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropa-thy in adults. Nat Clin Pract Nephrol 2008;4:327-336. (Pubitemid 351769331)
17. Kostler H, Landschutz W, Koeppe S, Seyfarth T, Lipke C, Sandstede J, Spindler M, von Kienlin M, Hahn D, Beer M. Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy. Magn Reson Med 2006;56:907-911. (Pubitemid 44477674)
18. Sandstede J, Lipke C, Beer M, Hofmann S, Pabst T, Kenn W, Neubauer S, Hahn D. Age- and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging. Eur Radiol 2000;10: 438-442. (Pubitemid 30145755)
19. Meininger M, Landschutz W, Beer M, Seyfarth T, Horn M, Pabst T, Haase A, Hahn D, Neubauer S, von Kienlin M. Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 1999;41:657-663. (Pubitemid 29205711)
20. Bottomley PA. The true T1 values of myocardial high-energy phosphates? Magn Reson Med 1993;29:145-147.
21. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35-43. (Pubitemid 127454051)
22. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multi-systemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346. (Pubitemid 36205932)
23. Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen PS, Hasholt L, Norremolle A, Feldt-Rasmussen U, Kober L, Bundgaard H. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail 2010; 12:535-540.
24. Weidemann F, Niemann M. Screening for Fabry disease using genetic testing. Eur J Heart Fail 2010;12:530-531.
25. Das AM. Regulation of the mitochondrial ATP-synthase in health and disease. Molecular genetics and metabolism 2003;79:71-82. (Pubitemid 36693924)
26. Das AM, Harris DA. Regulation of the mitochondrial ATP synthase in intact rat cardiomyocytes. The Biochem J 1990;266:355-361. (Pubitemid 20090132)
27. Strasberg PM, Callahan JW. Lysosphingolipids and mitochondrial function. II. Deleterious effects of sphingosylphosphorylcholine. Biochem Cell Biol 1988;66: 1322-1332. (Pubitemid 19076040)
28. Esposito A, De Cobelli F, Perseghin G, Pieroni M, Belloni E, Mellone R, Canu T, Gentinetta F, Scifo P, Chimenti C, Frustaci A, Luzi L, Maseri A, Maschio AD. Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging. Heart 2009;95:228-233.
29. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146:77-86. (Pubitemid 351640010)
30. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agal-sidase alfa. Heart 2008;94:153-158. (Pubitemid 351211719)
31. Beyerbacht HP, Lamb HJ, van Der Laarse A, Vliegen HW, Leujes F, Hazekamp MG, de Roos A, van Der Wall EE. Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. Radiology 2001;219:637-643. (Pubitemid 32476250)
32. Yabe T, Mitsunami K, Okada M, Morikawa S, Inubushi T, Kinoshita M. Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise. Circulation 1994;89:1709-1716.
33. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24(Suppl. 2):13-14; discussion 11-12.
34. Bottomley PA, Wu KC, Gerstenblith G, Schulman SP, Steinberg A, Weiss RG. Reduced myocardial creatine kinase flux in human myocardial infarction: an in vivo phosphorus magnetic resonance spectroscopy study. Circulation 2009;119: 1918-1924.
35. Imbriaco M, Spinelli L, Cuocolo A, Maurea S, Sica G, Quarantelli M, Pisani A, Liuzzi R, Cianciaruso B, Sabbatini M, Salvatore M. MRI characterization of myocar-dial tissue in patients with Fabry's disease. Am J Roentgenol 2007;188:850-853.